REGN — Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: Increased by 19% year-over-year to $3.6 billion.
• Non-GAAP Earnings Per Share: Rose 15% to $9.47, with net income of $1 billion.
• DUPIXENT Sales: Achieved $4.9 billion in global net sales, a 31% increase on a constant currency basis.
• EYLEA HD Sales: U.S. net sales grew 52% year-over-year to $468 million.
• Libtayo Sales: Increased by 54% to $438 million, driven by new indications.
• Sanofi Collaboration Revenue: Totaled $1.6 billion, with Regeneron's share of profits up 42%.

2. Strategic Updates and Business Highlights

• DUPIXENT: Continues to expand its market presence with recent approvals for new indications, including allergic fungal rhinosinusitis and chronic spontaneous urticaria.
• EYLEA HD: Strong physician adoption and a resubmitted application for a prefilled syringe, with anticipated FDA decisions on pending applications.
• Pipeline Progress: FDA approval of Otarmeni for genetic hearing loss, and positive Phase III data for cemdisiran in generalized myasthenia gravis.
• Capital Allocation: New $3 billion share repurchase program authorized, reflecting confidence in the business.
• Government Pricing Agreement: Entered into a Most Favored Nation pricing agreement with the U.S. government to lower drug prices while maintaining innovation.

3. Forward Guidance and Outlook

• Financial Guidance: Minor adjustments made, with GAAP gross margin expected to be between 77% and 78% due to temporary manufacturing interruptions.
• Sales Growth: Continued growth expected for DUPIXENT and EYLEA HD, with potential for Libtayo to gain further traction in new indications.
• Regulatory Decisions: Anticipated FDA decisions on EYLEA HD applications and cemdisiran expected in Q4 2026.

4. Bad News, Challenges, or Points of Concern

• EYLEA Sales Decline: EYLEA's U.S. net sales declined by 36% year-over-year, attributed to conversion to EYLEA HD, competitive pressures, and patient affordability issues.
• Pending FDA Applications: Delays in FDA action on EYLEA HD applications raise concerns about potential regulatory hurdles.
• Manufacturing Issues: Temporary interruption in production at the Limerick, Ireland facility impacted GAAP gross margin and could affect product availability.

5. Notable Q&A Insights

• DUPIXENT Collaboration: Management expressed openness to explore life cycle expansion efforts with Sanofi, indicating a willingness to leverage existing capabilities.
• Fianlimab in Lung Cancer: Management noted that data did not support moving to Phase III trials for lung cancer, indicating a focus on melanoma instead.
• EYLEA Prefilled Syringe: Clarification on the pending FDA applications, with optimism for resolution based on ongoing discussions with the FDA.
• Lynozyfic in Multiple Myeloma: Discussion on the competitive landscape of bispecific therapies and the importance of managing infection risks in earlier-stage patients.
• Next-Gen DUPIXENT: Emphasis on the importance of advancing late-stage programs before potential patent expirations, with a focus on innovative approaches to immunology.

Overall, Regeneron demonstrated strong financial performance in Q1 2026, driven by robust sales of key products and strategic advancements in its pipeline, while facing challenges related to EYLEA sales and regulatory processes.